Hit enter to search or ESC to close
No menu assigned
NeonMind Developing Music Playlist for Psychedelic Therapy Sessions
NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference
NeonMind CEO Provides Update on the Progress of its Psilocybin Drug Development Research Plan and Team
NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity
NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity
NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial
NeonMind Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight Stress
NeonMind Appoints Robert Tessarolo as President and Chief Executive Officer
©2021 NeonMind Biosciences Inc.
©2020 NeonMind Biosciences Inc.